Windtree Therapeutics Reports Fourth Quarter 2019 Financial

|Apr 2|magazine31 min read

WARRINGTON, Pa., April 2, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today reported financial results for the fourth quarter ended December 31, 2019 and provided key business updates. 

Key Business and Financial Updates

  • In December 2019, the Company completed a $26.4 million private placement of common stock and warrants. After offering expenses and the cancellation of $2.95 million of existing indebtedness in exchange for the securities offered, the Company received net proceeds of approximately $23.0 million.
  • The Company recently announced that it is developing plans to study its KL4 surfactant for treatment of lung injury resulting from severe COVID-19 infection, if it is able to secure the required additional capital resources necessary to initiate and complete the study. The Company is actively pursuing multiple non-dilutive funding opportunities, including from government agencies and private foundations.
  • In March 2020, the Company entered into a binding term sheet  with Lee's Pharmaceutical Holdings (HK) Ltd ("Lee's") pursuant to which Lee's will provide up to $3.9 million of non-dilutive project funding  for the six month period beginning April 1, 2020  for the continued development of the Company's lead acute pulmonary product candidate, AEROSURF® for the treatment of preterm infants with respiratory distress syndrome ("RDS").  The financing will fund the AEROSURF phase 2b bridge study, which if successful, is intended to transition the product into a phase 3 ready clinical program. The Company and Lee's will negotiate, in good faith, the terms of a definitive agreement that will set forth additional semi-annual non-refundable payments to fund the continued development of AEROSURF subsequent to September 30, 2020.  The arrangement is intended to fund the AEROSURF bridge study, as well as support the Company's focus of cash resources on opportunities in our istaroxime cardiovascular clinical programs. 
  • In March 2020, the AEROSURF bridge study clinical sites in Poland were initiated. Notwithstanding certain delays to ensure appropriate staffing and evolving COVID-19 hospital procedures are put into place, these study sites are still active, and the Company anticipates first patient dosed early in the second quarter.   
  • As of December 31, 2019, the Company had cash and cash equivalents of $22.6 million and current liabilities of $7.8 million.
  • In March 2020, the Company amended its bank credit facility agreement ($4.6 million outstanding as of December 31, 2019) to extend the maturity date from March 2020 to March 2022. 

"We made tremendous progress in 2019, capped by a $26 million private placement closed during the fourth quarter. Our strengthened balance sheet allows us to focus on our multiple clinical development programs as we move forward with istaroxime for early cardiogenic shock and acute heart failure study start-up activities, and with AEROSURF for respiratory distress syndrome in premature infants. Additionally, we have applied for a listing on the Nasdaq Capital Market and are working to secure this objective," commented Craig Fraser, President and Chief Executive Officer of Windtree. "While we are certain of our ability to execute upon our strategic plan, we are faced with uncertainty as our nation and global communities combat the global pandemic and impacts of COVID-19.  We are committed to help mitigate the devastating impact of this virus and announced recently our intent to pursue a clinical study treating patients with COVID-19 lung injury with our KL4 surfactant therapy upon securing the non-dilutive capital resources to fully fund the study. Along with clinical development, we are highly engaged in business development activities. The December 2018 acquisition of additional late stage products focused on areas with high unmet need along with successful financings to execute against these opportunities, have positioned Windtree for sustained growth and success. We are optimistic about the prospects for the Company and look forward to keeping our stakeholders updated in the coming months."

Select Financial Results for the Fourth Quarter ended December 31, 2019

For the quarter ended December 31, 2019, the Company reported an operating loss of $4.6 million, compared to $4.9 million for the fourth quarter of 2018.

Research and development expenses were $2.1 million for the fourth quarter of 2019, compared to $2.4 million for the fourth quarter of 2018. The decrease in research and development expenses is primarily due to a decrease in employee incentive compensation expense.

General and administrative expenses for the fourth quarter of 2019 were $2.4 million, compared to $2.8 million for the fourth quarter of 2018. The decrease in general and administrative expenses is primarily due to decreases in employee incentive compensation expense and professional fees, partially offset by an increase in non-cash stock compensation expense.

In the fourth quarter of 2019, the Company recorded a $1.8 million net loss on debt extinguishment as a result of the conversion of $2.95 million of existing loans payable obligations as part of the December 2019 private placement financing. In the fourth quarter of 2018, the Company recorded a $3.3 million net loss on debt extinguishment as a result of the conversion of $6.0 million of existing loans payable obligations as part of a December 2018 private placement financing.

The Company reported a net loss of $7.4 million ($0.21 per basic share) on 34.6 million weighted-average common shares outstanding for the quarter ended December 31, 2019, compared to a net loss of $23.6 million ($3.24 per basic share) on 7.2 million weighted average common shares outstanding for the comparable period in 2018. The 2018 net loss includes a $12.5 million charge related to issuance of the AEROSURF warrant dividend and a $1.7 million charge for a non-cash deemed dividend on preferred stock.

As of December 31, 2019, the Company reported cash and cash equivalents of $22.6 million, current liabilities of $7.8 million and loans payable – non-current of $4.6 million. The loans payable – non-current is payable in March 2022.

Readers are referred to, and encouraged to read in its entirety, the Company's Annual Report on Form 10-K for the year ended December 31, 2019 which will be filed with the Securities and Exchange Commission on April 3, 2020, which includes detailed discussions about the Company's business plans and operations, financial condition and results of operations.

About Windtree Therapeutics

Windtree Therapeutics, Inc. is a clinical-stage, biopharmaceutical and medical device company focused on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. Windtree has three lead clinical development programs spanning respiratory and cardiovascular disease states, including istaroxime, a novel, dual-acting agent being developed to improve cardiac function in patients with acute heart failure and cardiogenic shock; AEROSURF®, an innovative combination drug/device product candidate that is designed to deliver the Company's proprietary synthetic, peptide-containing surfactant noninvasively to premature infants with respiratory distress syndrome (RDS); and rostafuroxin, a novel precision drug product being developed to target hypertensive patients with certain genetic profiles in the important group of patients with resistant hypertension. Windtree also has multiple pre-clinical programs, including potential heart failure therapies delivered orally that are based on SERCA2a mechanism of action.

For more information, please visit the Company's website at www.windtreetx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include: risks and uncertainties associated with the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the company's clinical trials or disruption in supply chain; the success and advancement of the  clinical development programs for istaroxime,  AEROSURF® and the Company's other product candidates; the Company's ability to secure significant additional capital as and when needed; the Company's ability to access the debt or equity markets; the Company's ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, aerosol delivery systems (ADS) and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the FDA or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company's  product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company's efforts to maintain and protect the patents and licenses related to its product candidates; risks related to the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; and the rate and degree of market acceptance of the Company's product candidates, if approved.  These and other risks are described in the Company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

 




Windtree Therapeutics, Inc.




Consolidated Statements of Operations




(in thousands, except per share data)














Three Months Ended


Twelve Months Ended




December 31,


December 31,




2019


2018


2019


2018

Revenues:










Grant revenue

$                 –


$                 –


$                  –


$             765


License revenue with affiliate


304


198


1,023





304


198


1,788











Operating expenses: (1)









Research and development

2,140


2,368


12,687


10,562


General and administrative

2,414


2,787


12,404


7,421



Total operating expenses

4,554


5,155


25,091


17,983











Operating loss

(4,554)


(4,851)


(24,893)


(16,195)












Net loss on debt extinguishment

(1,794)


(3,345)


(1,794)


(3,345)


Interest and other income / (expense), net

(1,027)


(846)


(788)


(993)

Net loss

$      (7,375)


$        (9,042)


$     (27,475)


$    (20,533)









AEROSURF warrant dividend


(12,505)



(12,505)

Deemed dividend on Series A preferred stock


(1,718)



(1,718)

Net loss attributable to common shareholders

$      (7,375)


(23,625)


$    (27,475)


$    (34,756)









Net loss per common share – basic and diluted

$        (0.21)


$        (3.24)


$        (0.84)


$        (7.74)









Weighted avg. common shares outstanding – basic and diluted

34,597


7,191


32,784


4,493











(1)        For the three months ended December 31, 2019 and 2018, the charges for depreciation and stock-based compensation were $1.5 million ($0.3 million in R&D and $1.2 million in G & A) and $0.3 million ($0.1 million in R&D and $0.2 million in G & A), respectively. For the twelve months ended December 31, 2019 and 2018, the charges for depreciation and stock-based compensation were $6.9 million ($2.1 million in R&D and $4.8 million in G & A) and $1.1 million ($0.4 million in R&D and $0.7 million in G & A), respectively.

 

Windtree Therapeutics, Inc.

Consolidated Balance Sheets

(in thousands)






December 31,


December 31,






2019


2018

ASSETS





Current Assets:






Cash and cash equivalents


$                 22,578


$                 11,187


Available-for-sale marketable securities



13,959


Prepaid expenses and other current assets


1,283


507




Total current assets


23,861


25,653









Property and equipment, net


798


802

Restricted cash


154


171

Operating lease right-of-use assets


1,390


Intangible assets


77,090


77,090

Goodwill


15,682


15,682



Total Assets


$              118,975


$              119,398









LIABILITIES AND STOCKHOLDERS' EQUITY





Current Liabilities:






Accounts payable, collaboration and device development payable and accrued expenses


$                  6,906


$                12,461


Operating lease liabilities – current portion


750



Deferred revenue – current portion



198


Loans payable – current portion


161


7,974




Total current liabilities


7,817


20,633









Operating lease liabilities – non-current portion


794


Loans payable – non-current portion


4,608


Restructured debt liability – contingent milestone payments


15,000


15,000

Deferred tax liabilities


15,821


15,476

Other liabilities



175

Stockholders' Equity


74,935


68,114



Total Liabilities and Stockholders' Equity


$              118,975


$             119,398

 

Cision View original content:http://www.prnewswire.com/news-releases/windtree-therapeutics-reports-fourth-quarter-2019-financial-results-and-provides-key-business-updates-301034568.html

SOURCE Windtree Therapeutics, Inc.